(MENAFN- GetNews)


"Dengue Fever Clinical Trials"DelveInsight's,“Dengue Fever - Pipeline Insight, 2025” report provides comprehensive insights about 8+ companies and 10+ pipeline drugs in Dengue Fever pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

According to DelveInsight, the Dengue Fever pipeline includes 8+ key companies actively engaged in developing 10+ therapeutic candidates targeting dengue infection.

Dengue Fever Overview:

Dengue fever is a mosquito-borne viral disease transmitted mainly by Aedes aegypti mosquitoes. It is prevalent across tropical and subtropical regions, especially in Southeast Asia, the Pacific Islands, the Caribbean, and Central and South America. The disease typically presents with sudden high fever, severe headache, retro-orbital pain, joint and muscle pain, rash, and minor bleeding symptoms such as nose or gum bleeding. Symptoms usually appear 4–10 days after infection and last for 2–7 days.

The illness varies in severity, ranging from mild fever to severe dengue, which encompasses dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS). Severe cases are characterized by intense abdominal pain, persistent vomiting, bleeding tendencies, fatigue, and potential circulatory collapse. Without proper medical intervention, these complications can result in shock, organ failure, or death. Children and individuals with secondary infections are at higher risk of developing severe disease.

Currently, there are no approved antiviral treatments for dengue; management remains supportive, focusing on symptom relief and fluid replacement. Preventive measures are crucial and include avoiding mosquito bites, using repellents, wearing protective clothing, and eliminating mosquito breeding sites.

Vaccination efforts are ongoing-Dengvaxia, the first licensed dengue vaccine, has been approved in select endemic areas but is recommended only for individuals previously infected with dengue due to increased risk of severe disease in dengue-naïve individuals. Continued progress in vaccine development, mosquito control, and public health strategies remains key to curbing transmission and preventing outbreaks.

Request for a detailed insights report on Dengue Fever pipeline insights

DelveInsight's“Dengue Fever Pipeline Insight 2025” report offers an in-depth evaluation of the current clinical development landscape and future growth opportunities within the Dengue Fever Therapeutics Market.

Key Takeaways from the Dengue Fever Pipeline Report

• DelveInsight's Dengue Fever pipeline report highlights a dynamic landscape, featuring 200+ active companies engaged in developing over 200 therapeutic candidates for Dengue Fever treatment.

• In June 2025, Merck (MSD) initiated MOBILIZE-1, the first Phase III clinical trial for its investigational single-dose, quadrivalent dengue vaccine V181. This randomized, double-blind, placebo-controlled study has started enrolling participants, with the first recruits in Singapore, and plans to include approximately 12,000 children aged 2–17 years across 30+ dengue-endemic sites in the Asia–Pacific region.

• Leading companies such as Johnson & Johnson, Novartis Pharmaceuticals, Merck Sharp & Dohme LLC, Panacea Biotec, Codagenix, and others are advancing new therapeutic approaches to transform the Dengue Fever treatment landscape.

• Notable pipeline candidates in various development stages include V181, EYU-688, and several others.

Dengue Fever Pipeline Analysis

The report provides insights into:

• The report provides detailed insights into the key companies that are developing therapies in the Dengue Fever Market.

• The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Dengue Fever treatment.

• It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

• It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Dengue Fever market.

Download our free sample page report on Dengue Fever pipeline insights

Dengue Fever Emerging Drugs

V181 – Merck Sharp & Dohme LLC

V181 is an investigational quadrivalent dengue vaccine developed by Merck & Co. to prevent dengue fever-a mosquito-borne viral infection prevalent in tropical and subtropical regions. The vaccine employs purified inactivated virus (PIV) technology, similar to that used in other inactivated viral vaccines, to elicit a robust immune response without causing infection.

Preliminary findings suggest that V181 induces a balanced immune response across all four dengue virus serotypes, aiming to reduce both infection risk and the likelihood of severe outcomes such as dengue hemorrhagic fever. The vaccine candidate is currently undergoing Phase II clinical evaluation.

EYU-688 – Novartis Pharmaceuticals

EYU-688 is an investigational oral small-molecule therapy being developed by Novartis for the treatment of dengue fever. It functions by inhibiting nonstructural protein 4B (NS4B)-a key component required for viral replication-and also interacts with the somatostatin receptor (SSTR). The candidate is currently in Phase II clinical trials for dengue treatment.

Dengue Fever Companies

Approximately eight or more major pharmaceutical companies are actively developing therapies for dengue fever, with Merck Sharp & Dohme LLC and Novartis Pharmaceuticals advancing the most progressed candidates, both currently in Phase II clinical development.

Request the Sample PDF to Get Detailed Insights About the Dengue Fever Pipeline Reports Offerings

DelveInsight's report covers around 75+ products under different phases of clinical development like

• Late stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I) along with the details of

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

Dengue Fever pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intravenous

• Subcutaneous

• Oral

• Intramuscular

Dengue Fever Products have been categorized under various Molecule types such as

• Monoclonal antibody

• Small molecule

• Peptide

Download Sample Pages to Get an in-depth Assessment of the Emerging Dengue Fever Therapies and Key Companies: Dengue Fever Clinical Trials and assessment

Dengue Fever Pipeline Therapeutic Assessment

. Dengue Fever Assessment by Product Type

. Dengue Fever By Stage

. Dengue Fever Assessment by Route of Administration

. Dengue Fever Assessment by Molecule Type

Download Dengue Fever Sample report to know in detail about the Dengue Fever treatment market @ Dengue Fever Therapeutic assessment

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

MENAFN03112025003238003268ID1110288806